Since its beginning in 1992, Angiotech Pharmaceuticals, Inc. has evolved from a global specialty pharmaceutical company to a medical device company and more recently to a wound closure company. During its 'specialty pharmaceutical' days Angiotech developed a differentiated R&D effort that focused on drug-medical device combinations for implantable, surgical products and acute trauma applications – this is no longer a focus of Angiotech. more... See more text